Besidi

Besidi is a biotechnology company dedicated to the development of next-generation cell therapies for the treatment of solid tumors. The company utilizes a proprietary CRISPR-based functional genomics platform, originally developed at Yale University, to identify novel genetic modifications that enhance the potency and persistence of immune cells. By engineering CAR-T and CAR-NK cells with these optimized genetic profiles, Besidi aims to overcome the immunosuppressive barriers of the tumor microenvironment. Their approach focuses on systematic, high-throughput screening to discover unique combinations of gene edits that drive superior anti-tumor activity and durability.